Getein Biotech, Inc

Shanghai Stock Exchange 603387.SS

Getein Biotech, Inc EBIT for the year ending December 31, 2023: USD 45.78 M

Getein Biotech, Inc EBIT is USD 45.78 M for the year ending December 31, 2023, a -45.19% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Getein Biotech, Inc EBIT for the year ending December 31, 2022 was USD 83.53 M, a 14.00% change year over year.
Getein Biotech, Inc EBIT for the year ending December 31, 2021 was USD 73.27 M, a 24.95% change year over year.
Getein Biotech, Inc EBIT for the year ending December 31, 2020 was USD 58.64 M, a 2.66% change year over year.
Getein Biotech, Inc EBIT for the year ending December 31, 2019 was USD 57.12 M, a 57.71% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

Shanghai Stock Exchange: 603387.SS

Getein Biotech, Inc

CEO	Mr. Gang Zhu
IPO Date	July 17, 2017
Location	China
Headquarters	No.9 Bofu Road
Employees	2,508
Sector	Health Care
Industries Biotechnology Chemicals & Advanced Materials Medical Instruments Pharmaceuticals

Description

Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic products in China and internationally. The company provides diagnostic reagents and analyzers; calibrators; reagent raw materials, such as monoclonal and polyclonal antibodies, antigen, antiserum, and microsphere; and cardiac marker, inflammation, renal function, coagulation, thyroid function, fertility, diabetes care, and thrombus products. It also offers products in the area of cardiovascular, inflammatory, diabetes, fertility, renal, liver, and others. The company was founded in 2002 and is headquartered in Nanjing, China.

Key trends

Past 5 years